Department of Pharmacy Intern, Nirmala College of Pharmacy, India
Research
Post Tace Hepatocellular Carcinoma Response Assessment by Modified Recist and Short Term Post Tace Survival
Author(s): Bony George*, Krishnadas Devadas, Sandesh K, Jineesh V, Tharun Tom Oomen, Jijo Varghese, Arun P, Eldhose Elias George and Vijay Narayanan
Background and aims: Transarterial chemoembolization (TACE) can improve the overall survival of patients with
intermediate-stage HCC. A modified response evaluation criterion in solid tumours (mRECIST) is used for evaluation
of the treatment response in patients after TACE. We tried to evaluate the response and survival in patients
after TACE.
Methods: Patients underwent superselective TACE with Epirubicin. The mRECIST response was calculated after 6
weeks using MRI. Predictive factors were calculated for response and survival
Results: 42 patients with intermediate HCC were analysed. The mean age was 59.12 ± 8.74 years. The predominant
etiology was NASH in 31% and alcohol in 23.8%. 23 patients had complete response (CR), 8 patients had partial
response (PR), 4 patients had stable disease (SD) a.. View More»
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 